Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Hypertension HELP
Based on 81,364 articles published since 2010
|||| 36 

These are the 81364 published articles about Hypertension that originated from Worldwide during 2010-2020.
 
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10 · 11 · 12 · 13 · 14 · 15 · 16 · 17 · 18 · 19 · 20
1 Guideline [Austrian Consensus on High Blood Pressure 2019]. 2019

Weber, Thomas / Arbeiter, Klaus / Ardelt, Florian / Auer, Johann / Aufricht, Christoph / Brandt, Mathias C / Dichtl, Wolfgang / Ferrari, Julia / Föger, Bernhard / Henkel, Martin / Hohenstein-Scheibenecker, Katharina / Horn, Sabine / Kautzky-Willer, Alexandra / Kepplinger, Erwin / Knoflach, Michael / Koppelstätter, Christian / Mache, Christoph / Marschang, Peter / Mayer, Gert / Metzler, Bernhard / Oberbauer, Rainer / Obermair, Florian / Obermayer-Pietsch, Barbara / Perl, Sabine / Pilz, Stefan / Prischl, Friedrich C / Podczeck-Schweighofer, Andrea / Rebhandl, Erwin / Rohla, Miklos / Roller-Wirnsberger, Regina / Saely, Christoph H / Siostrzonek, Peter / Slany, Jörg / Stoschitzky, Kurt / Waldegger, Siegfried / Wenzel, Rene R / Weiss, Thomas / Wirnsberger, Gerhard / Winhofer-Stöckl, Yvonne / Zweiker, David / Zweiker, Robert / Watschinger, Bruno / Anonymous7861019 / Anonymous7871019 / Anonymous7881019 / Anonymous7891019 / Anonymous7901019 / Anonymous7911019 / Anonymous7921019 / Anonymous7931019 / Anonymous7941019 / Anonymous7951019 / Anonymous7961019 / Anonymous7971019 / Anonymous7981019. ·Abteilung für Innere Medizin II - Kardiologie, Intensivmedizin, Klinikum Wels-Grieskirchen, Grieskirchnerstraße 42, 4600, Wels, Österreich. · Universitätsklinik für Kinder- und Jugendheilkunde, Abteilung Pädiatrische Nephrologie und Gastroenterologie, Medizinische Universität Wien, Wien, Österreich. · Gemeinschaftspraxis für Allgemeinmedizin, Marchtrenk, Österreich. · Interne Abteilung, Krankenhaus Sankt Josef Braunau, Braunau, Österreich. · Klinik II für Innere Medizin, Universitätsklinikum Salzburg, Müllner Hauptstraße 48, 5020, Salzburg, Österreich. · Universitätsklinik für Innere Medizin III - Kardiologie und Angiologie, Medizinische Universität Innsbruck, Anichstraße 35, 6020, Innsbruck, Österreich. · Abteilung für Neurologie, neurologische Rehabilitation und Akutgeriatrie, Krankenhaus der Barmherzigen Brüder Wien, Wien, Österreich. · Abteilung für Innere Medizin, Krankenhaus Pfarrkirchen, Pfarrkirchen, Österreich. · Abteilung für Kinder- und Jugendheilkunde, Ordensklinikum Linz Barmherzige Schwestern, Linz, Österreich. · Pflegewohnhaus Donaustadt, Sozialmedizinisches Zentrum Ost - Wiener Krankenanstaltenverbund, Langobardenstaße 122a, 1220, Wien, Österreich. · Abteilung für Innere Medizin, Landeskrankenhaus Villach, Villach, Österreich. · Klinik für Innere Medizin III, Abteilung für Endokrinologie und Stoffwechsel, Medizinische Universität Wien, Wien, Österreich. · Gemeinschaftspraxis für Allgemeinmedizin Leonding, Leonding, Österreich. · Universitätsklinik für Neurologie, Medizinische Universität Innsbruck, Anichstraße 35, 6020, Innsbruck, Österreich. · Universitätsklinik für Innere Medizin IV, Medizinische Universität Innsbruck, Anichstraße 35, 6020, Innsbruck, Österreich. · Universitätklinik für Kinder- und Jugendheilkunde, Klinische Abteilung für Allgemeine Pädiatrie, Medizinische Universität Graz, Graz, Österreich. · Abteilung für Innere Medizin, Zentralkrankenhaus Bozen, Lorenz-Böhler-Straße 5, 39100, Bozen, Italien. · Klinik für Innere Medizin III, Abteilung für Nephrologie und Dialyse, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Wien, Österreich. · Praxis für Allgemeinmedizin, Eberschwang, Österreich. · Universitätsklinik für Innere Medizin, Klinische Abteilung für Endokrinologie und Diabetologie, Medizinische Universität Graz, Graz, Österreich. · Abteilung für Kardiologie, Medizinische Universität Graz, Auenbruggerplatz 15, 8036, Graz, Österreich. · 4. Interne Abteilung, Bereich Nephrologie, Klinikum Wels-Grieskirchen, 4600, Wels, Österreich. · 5. Medizinische Abteilung/Kardiologie, Kaiser Franz Josef-Spital, Wien, Österreich. · Primärversorgungszentrum Haslach, Haslach an der Mühl, Österreich. · 3. Medizinische Abteilung, Kardiologie und internistische Intensivmedizin, Wilhelminenspital, Wien, Österreich. · Universitätsklinik für Innere Medizin, Gemeinsame Einrichtung, Medizinische Universität Graz, Auenbruggerplatz 15, 8036, Graz, Österreich. · Landeskrankenhaus Feldkirch, Akademisches Lehrkrankenhaus, 6800, Feldkirch, Österreich. · VIVIT Institut, Feldkirch, Österreich. · Private Universität im Fürstentum Liechtenstein (UFL), Triesen, Liechtenstein. · Interne II - Kardiologie, Ordensklinikum Linz Barmherzige Schwestern, Seilerstätte 4, 4060, Linz, Österreich. · , Promenadengasse 21/3, 1170, Wien, Österreich. · Tirolkliniken, Pädiatrie I, Medizinische Universität Innsbruck, Innsbruck, Österreich. · Interne Abteilung, A.ö. Tauernkliniken - Zell am See & Mittersill, Paracelsusstr. 8, 5700, Zell am See, Österreich. · Privatklinik Döbling, Wien, Österreich. · Karl Landsteiner Institut für Kardiometabolik, St. Pölten, Österreich. · Lehrstuhl für experimentelle Kardiologie, Sigmund Freud PrivatUniversität Wien, Wien, Österreich. · Medizinische Universität Graz, Klinische Abteilung für Nephrologie, Universitätsklinik für Innere Medizin, Auenbruggerplatz 27, 8036, Graz, Österreich. ·Wien Klin Wochenschr · Pubmed #31792659.

ABSTRACT: Elevated blood pressure remains a major cause of cardiovascular disease, disability, and premature death in Austria, with suboptimal rates of detection, treatment and control also in recent years. Management of hypertension is a common challenge for physicians with different spezializations. In an attempt to standardize diagnostic and therapeutic strategies and, ultimately, to increase the rate of patients with controlled blood pressure and to decrease the burden of cardiovascular disease, 13 Austrian medical societies reviewed the evidence regarding prevention, detection, workup, treatment and consequences of high blood pressure in general and in various clinical scenarios. The result is presented as the first national consensus on blood pressure. The authors and societies involved are convinced that a joint national effort is needed to decrease hypertension-related morbidity and mortality in our country.

2 Guideline [Expert consensus statement on blood pressure measurement from the French Society of Hypertension, an affiliate of the French Society of Cardiology]. 2019

Denolle, Thierry / Anonymous1681018 / Anonymous1691018. ·Société française d'hypertension artérielle, 5, rue des Colonnes-du-Trône, 75012 Paris, France. Electronic address: denolle.thierry@wanadoo.fr. ·Presse Med · Pubmed #31732365.

ABSTRACT: Since 2016, the French Society of Hypertension has warned about the decline in the management of high blood pressure in France: stagnation, or even decreased number of people who know their blood pressure level, take a treatment and are controlled. These results are lower than those observed in many other countries. Blood pressure is measured with an old method in the doctor's office. Accepted, simple and cost-effective, this method is currently unavoidable for reasons of feasibility and social habit. It has been used in observational and intervention studies that are the basis of the medical reasoning for screening, treatment and drug control of hypertension. In practice, it is too often poorly applied and unpredictable. It is now necessary to measure blood pressure in mmHg using a validated oscillometric automatic device coupled to a specific upper arm cuff adapted to the arm circumferences for the diagnosis and monitoring of high blood pressure in the doctor's office and at home. The auscultatoric measurement is only recommended if any doubt about the reliability of the electronic measurement. Blood pressure measurement is basically performed on both arms to detect asymmetry and then on the arm with the highest blood pressure. It is performed in sitting or lying position after a few minutes of rest without speaking and without having smoked and then in standing position to diagnose orthostatic hypotension, especially in elderly, diabetic and multi-medicated subjects. The blood pressure measurement during the consultation must be repeated and include at least 3 consecutive measurements at one minute intervals. The average of the last 2 measurements determines the blood pressure level. It is recommended to perform BP measurements outside the medical environment for the diagnosis and monitoring of hypertension; Home BP measurement is preferred to ambulatory blood pressure measurement for practical reasons unless otherwise specified. The home blood pressure measurement should include three measurements in the morning at breakfast and three measurements in the evening before bedtime at one minute intervals for at least three days. Prior training must be provided. In treated hypertensive patients, a masked hypertension should be considered as an uncontrolled hypertension and antihypertensive therapy adapted accordingly. The measurement of central BP pressure (aorta) should be limited to clinical research.

3 Guideline [CCI clinical practice guidelines: management of TIPS for portal hypertension (2019 edition)]. 2019

Anonymous8111006. · ·Zhonghua Gan Zang Bing Za Zhi · Pubmed #31594075.

ABSTRACT: Portal hypertension(PH) is one of the main complications of cirrhosis.Transjugular intrahepatic portosystemic shunt(TIPS) is the percutaneous creation of a conduit from the hepatic vein to the portal vein that is used to manage consequences of PH (i.e., variceal bleeding and refractory ascites) and used as a bridging therapy to liver transplant for decompensated cirrhosis. The following Clinical Practice Guidelines (CPGs) presents profession associational recommendations of the Chinese College of Interventionalists(CCI) on TIPS for PH. The CPGs was written by more than 30 experts in the field of TIPS in China (including interventional radiologists, liver surgeons, hepatologists and gastroenterologist, et al.). The panel of experts, produced these CPGs using evidence from PubMed and Cochrane database searches and combined with relevant expert consensuses and high quality clinical researches in China providing up to date guidance on TIPS for PH with the only purpose of improving clinical practice.

4 Guideline Diagnosis, Treatment and Follow Up of Acute Pulmonary Embolism: Consensus Practice from the PERT Consortium. 2019

Rivera-Lebron, Belinda / McDaniel, Michael / Ahrar, Kamran / Alrifai, Abdulah / Dudzinski, David M / Fanola, Christina / Blais, Danielle / Janicke, David / Melamed, Roman / Mohrien, Kerry / Rozycki, Elizabeth / Ross, Charles B / Klein, Andrew J / Rali, Parth / Teman, Nicholas R / Yarboro, Leoara / Ichinose, Eugene / Sharma, Aditya M / Bartos, Jason A / Elder, Mahir / Keeling, Brent / Palevsky, Harold / Naydenov, Soophia / Sen, Parijat / Amoroso, Nancy / Rodriguez-Lopez, Josanna M / Davis, George A / Rosovsky, Rachel / Rosenfield, Kenneth / Kabrhel, Christopher / Horowitz, James / Giri, Jay S / Tapson, Victor / Channick, Richard / Anonymous2171034. ·1 University of Pittsburgh, Pittsburgh, PA, USA. · 2 Emory University, Atlanta, GA, USA. · 3 The University of Texas MD Anderson Cancer Center, Houston, TX, USA. · 4 University of Miami of Palm Beach Regional Campus/JFK Hospital, Atlantis, FL, USA. · 5 Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. · 6 University of Minnesota, Minneapolis, MN, USA. · 7 The Ohio State University Wexner Medical Center, Columbus, OH, USA. · 8 University of Buffalo, Buffalo, NY, USA. · 9 Abbott Northwestern Hospital, Minneapolis, MN, USA. · 10 Temple University, Philadelphia, PA, USA. · 11 Piedmont Heart Institute, Atlanta, GA, USA. · 12 University of Virginia, Charlottesville, VA, USA. · 13 Oklahoma Heart Institute, Tulsa, OK, USA. · 14 Wayne State University, Detroit, MI, USA. · 15 Michigan State University, East Lansing, MI, USA. · 16 University of Pennsylvania, Philadelphia, PA, USA. · 17 Saint Louis University, St. Louis, MO, USA. · 18 Henry Ford Hospital, Detroit, MI, USA. · 19 New York University, New York, NY, USA. · 20 University of Kentucky, Lexington, KY, USA. · 21 Cedars-Sinai Medical Center, Los Angeles, CA, USA. · 22 University of California, Los Angeles, CA, USA. ·Clin Appl Thromb Hemost · Pubmed #31185730.

ABSTRACT: Pulmonary embolism (PE) is a life-threatening condition and a leading cause of morbidity and mortality. There have been many advances in the field of PE in the last few years, requiring a careful assessment of their impact on patient care. However, variations in recommendations by different clinical guidelines, as well as lack of robust clinical trials, make clinical decisions challenging. The Pulmonary Embolism Response Team Consortium is an international association created to advance the diagnosis, treatment, and outcomes of patients with PE. In this consensus practice document, we provide a comprehensive review of the diagnosis, treatment, and follow-up of acute PE, including both clinical data and consensus opinion to provide guidance for clinicians caring for these patients.

5 Guideline [Blood hypertension in childrens. Guideliness for diagnosis and treatment. Part 1. Pediatric Nephrology Branch, Chilean Pediatric Society]. 2019

Salas, Paulina / González, Claudia / Carrillo, Daniela / Bolte, Lilian / Aglony, Marlene / Peredo, Soledad / Ibarra, Ximena / Rojo, Angelica / Delucchi, Angela / Pinto, Viola / Saieh, Carlos / Ceballos, María L. ·Hospital Exequiel González Cortés, Chile. · Hospital Sótero del Río, Chile. · Hospital Roberto del Río, Chile. · Sociedad Chilena de Hipertensión, Chile. · Hospital Clínico, Pontificia Universidad Católica de Chile, Chile. · Hospital Luis Calvo Mackenna, Chile. · Clínica Las Condes, Chile. ·Rev Chil Pediatr · Pubmed #31095238.

ABSTRACT: Hypertension (HT) in children and adolescents is an important pathology, associated with modi fiable and non-modifiable factors. In the pediatric, the prevalence of HT is around 3.5%, and it in creases progressively with age. The ideal method for diagnosis is the measurement of blood pressure (BP) with auscultatory instruments. As published by the American Academy of Pediatrics (AAP), BP should be measured in children over 3 years of age once a year, and in children under 3 years of age, if it presents risk factors. Once HT has been confirmed, the evaluation should be directed towards the detection of a causative disease and the search for risk factors associated with primary HTN. The goal of treating primary and secondary HTN in pediatrics is to achieve a level of BP that decreases the risk of target organ damage. The therapeutic options include: treatment according to specific etiology, non-pharmacological and pharmacological. This document is the product of a collaborative effort of the Nephrology Branch of the Chilean Society of Pediatrics with the aim of helping pediatricians and pediatric nephrologists in the diagnosis and treatment of hypertension in childhood. In this first part, the recommendations of the diagnosis and study are presented.

6 Guideline [2018 ESC/ESH Guidelines for the management of arterial hypertension]. 2019

Williams, Bryan / Mancia, Giuseppe / Spiering, Wilko / Rosei, Enrico Agabiti / Azizi, Michel / Burnier, Michel / Clement, Denis L / Coca, Antonio / de Simone, Giovanni / Dominiczak, Anna / Kahan, Thomas / Mahfoud, Felix / Redon, Josep / Ruilope, Luis / Zanchetti, Alberto / Kerins, Mary / Kjeldsen, Sverre E / Kreutz, Reinhold / Laurent, Stephane / Lip, Gregory Y H / McManus, Richard / Narkiewicz, Krzysztof / Ruschitzka, Frank / Schmieder, Roland E / Shlyakhto, Evgeny / Tsioufis, Costas / Aboyans, Victor / Desormais, Ileana. ·Institute of Cardiovascular Science, University College London, Maple House, 1st Floor, Suite A, 149 Tottenham Court Road, W1T 7DN London, United Kingdom. bryan.williams@ucl.ac.uk. ·Kardiol Pol · Pubmed #30816983.

ABSTRACT: -- No abstract --

7 Guideline Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. 2019

Elmets, Craig A / Leonardi, Craig L / Davis, Dawn M R / Gelfand, Joel M / Lichten, Jason / Mehta, Nehal N / Armstrong, April W / Connor, Cody / Cordoro, Kelly M / Elewski, Boni E / Gordon, Kenneth B / Gottlieb, Alice B / Kaplan, Daniel H / Kavanaugh, Arthur / Kivelevitch, Dario / Kiselica, Matthew / Korman, Neil J / Kroshinsky, Daniela / Lebwohl, Mark / Lim, Henry W / Paller, Amy S / Parra, Sylvia L / Pathy, Arun L / Prater, Elizabeth Farley / Rupani, Reena / Siegel, Michael / Stoff, Benjamin / Strober, Bruce E / Wong, Emily B / Wu, Jashin J / Hariharan, Vidhya / Menter, Alan. ·University of Alabama, Birmingham, Alabama. · Central Dermatology, St. Louis, Missouri. · Mayo Clinic, Rochester, Minnesota. · University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania. · National Psoriasis Foundation, Portland, Oregon. · National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland. · University of Southern California, Los Angeles, California. · Department of Dermatology, University of California San Francisco School of MedicineSan Francisco, California. · Medical College of Wisconsin, Milwaukee, Wisconsin. · Department of Dermatology, Icahn School of Medicine at Mt. Sinai, New York, New York. · University of Pittsburgh, Pennsylvania. · University of California San Diego, San Diego, California. · Baylor Scott and White, Dallas, Texas. · University Hospitals Cleveland Medical Center, Cleveland, Ohio. · Massachusetts General Hospital, Boston, Massachusetts. · Department of Dermatology, Henry Ford Hospital, Detroit, Michigan. · Northwestern University Feinberg School of Medicine, Chicago, Illinois. · Dermatology and Skin Surgery, Sumter, South Carolina. · Colorado Permanente Medical Group, Centennial, Colorado. · University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma. · Icahn School of Medicine at Mount Sinai, New York, New York. · Emory University School of Medicine, Atlanta, Georgia. · University of Connecticut, Farmington, Connecticut; Probity Medical Research, Waterloo, Canada. · San Antonio Uniformed Services Health Education Consortium, Joint-Base San Antonio, Texas. · Dermatology Research and Education Foundation, Irvine, California. · American Academy of Dermatology, Rosemont, Illinois. Electronic address: vhariharan@aad.org. ·J Am Acad Dermatol · Pubmed #30772097.

ABSTRACT: Psoriasis is a chronic, inflammatory, multisystem disease that affects up to 3.2% of the US population. This guideline addresses important clinical questions that arise in psoriasis management and care, providing recommendations on the basis of available evidence.

8 Guideline Nutrients and Nutraceuticals for the Management of High Normal Blood Pressure: An Evidence-Based Consensus Document. 2019

Cicero, Arrigo F G / Grassi, Davide / Tocci, Giuliano / Galletti, Ferruccio / Borghi, Claudio / Ferri, Claudio. ·Medical and Surgical Sciences Dept, Sant'Orsola-Malpighi University Hospital, U.O. Medicina Interna Borghi, Via Albertoni, 15, 40138, Bologna, Italy. arrigo.cicero@unibo.it. · Department of Life, Health and Environmental Sciences, University of L'Aquila, Coppito, L'Aquila, Italy. · Division of Cardiology, Department of Clinical and Molecular Medicine, Faculty of Medicine and Psychology, Sant'Andrea Hospital, University of Rome Sapienza, Rome, Italy. · IRCCS Neuromed, Pozzilli, IS, Italy. · Department of Clinical Medicine and Surgery, ESH Excellence Center of Hypertension, "Federico II", University of Naples Medical School, Via S. Pansini, 5, 80131, Naples, Italy. · Medical and Surgical Sciences Dept, Sant'Orsola-Malpighi University Hospital, U.O. Medicina Interna Borghi, Via Albertoni, 15, 40138, Bologna, Italy. ·High Blood Press Cardiovasc Prev · Pubmed #30671873.

ABSTRACT: Essential hypertension still represents the most common cardiovascular risk factor, which is responsible for the vast majority of global burden of disease, worldwide. Antihypertensive treatment aimed at lowering blood pressure (BP) levels to the recommended therapeutic targets has demonstrated to reduce risk of developing major cardiovascular, cerebrovascular and renal complications. Despite these evidence, overall rates of BP control are dramatically low in most European and Western countries, as well as in the so called developing countries, thus contributing to the increasingly amount of hypertension-related costs and disabilities. For these reasons, preventive strategies aimed at improving BP control rates in treated hypertensive patients and reducing high-normal BP levels in asymptomatic otherwise healthy individuals may contribute to reduce the burden of disease related to hypertension. In this view, an extensive use of nutrients and nutraceuticals has demonstrated to provide favorable effects in hypertension management and control, beyond the adoption of pharmacological and non-pharmacological interventions. These interventions can effectively and safely reduce BP levels to targets and prevent disease progression form high-normal BP levels towards stage 1 hypertension. The present consensus document will systematically describe and critically analyze the currently available evidence in favor of the use of nutrients and nutraceuticals in those individuals with high-normal BP levels at different cardiovascular risk profile.

9 Guideline Therapy for Pulmonary Arterial Hypertension in Adults: Update of the CHEST Guideline and Expert Panel Report. 2019

Klinger, James R / Elliott, C Gregory / Levine, Deborah J / Bossone, Eduardo / Duvall, Laura / Fagan, Karen / Frantsve-Hawley, Julie / Kawut, Steven M / Ryan, John J / Rosenzweig, Erika B / Sederstrom, Nneka / Steen, Virginia D / Badesch, David B. ·Brown University, Providence, RI. · Intermountain Healthcare and the University of Utah School of Medicine, Murray, UT. · University of Texas Health Science Center at San Antonio, San Antonio, TX. · A. Cardarelli Hospital, Naples, Italy. · OhioHealth/The Ohio State University, Columbus, OH. · University of South Alabama, Mobile, AL. · CHEST, Glenview, IL. · Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA. · University of Utah, Salt Lake City, UT. · Columbia University Medical Center, New York, NY. · Children's Hospitals and Clinics of Minnesota, Minneapolis, MN. · Georgetown University Medical Center, Washington, DC. · University of Colorado School of Medicine, Aurora, CO. Electronic address: David.Badesch@ucdenver.edu. ·Chest · Pubmed #30660783.

ABSTRACT: BACKGROUND: Pulmonary arterial hypertension (PAH) carries a poor prognosis if not promptly diagnosed and appropriately treated. The development and approval of 14 medications over the last several decades have led to a rapidly evolving approach to therapy, and have necessitated periodic updating of evidence-based treatment guidelines. This guideline statement, which now includes a visual algorithm to enhance its clinical utility, represents the fourth iteration of the American College of Chest Physicians Guideline and Expert Panel Report on Pharmacotherapy for PAH. METHODS: The guideline panel conducted an updated systematic review to identify studies published after those included in the 2014 guideline. A systematic literature search was conducted using MEDLINE via PubMed and the Cochrane Library. The quality of the body of evidence was assessed for each critical or important outcome of interest using the Grading of Recommendations Assessment, Development and Evaluation approach. Graded recommendations and ungraded consensus-based statements were developed and voted on using a modified Delphi technique to achieve consensus. RESULTS: Two new recommendations on combination therapy and two ungraded consensus-based statements on palliative care were developed. An evidence-based and consensus-driven treatment algorithm was created to guide the clinician through an organized approach to management, and to direct readers to the appropriate area of the document for more detailed information. CONCLUSIONS: Therapeutic options for the patient with PAH continue to expand through basic discovery, translational science, and clinical trials. Optimal use of new treatment options requires prompt evaluation at an expert center, utilization of current evidence-based guidelines, and collaborative care using sound clinical judgment.

10 Guideline First International Consensus on the diagnosis and management of fibromuscular dysplasia. 2019

Gornik, Heather L / Persu, Alexandre / Adlam, David / Aparicio, Lucas S / Azizi, Michel / Boulanger, Marion / Bruno, Rosa Maria / de Leeuw, Peter / Fendrikova-Mahlay, Natalia / Froehlich, James / Ganesh, Santhi K / Gray, Bruce H / Jamison, Cathlin / Januszewicz, Andrzej / Jeunemaitre, Xavier / Kadian-Dodov, Daniella / Kim, Esther Sh / Kovacic, Jason C / Mace, Pamela / Morganti, Alberto / Sharma, Aditya / Southerland, Andrew M / Touzé, Emmanuel / van der Niepen, Patricia / Wang, Jiguang / Weinberg, Ido / Wilson, Scott / Olin, Jeffrey W / Plouin, Pierre-Francois. ·1 Division of Cardiovascular Medicine, University Hospitals Cleveland Medical Center and UH Harrington Heart and Vascular Institute, Cleveland, OH, USA. · 2 Division of Cardiology, Department of Cardiovascular Diseases, Cliniques Universitaires Saint-Luc and Pole of Cardiovascular Research, Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Brussels, Belgium. · 3 Department of Cardiovascular Sciences, Glenfield Hospital, Leicester, UK. · 4 NIHR Leicester Biomedical Research Centre, Glenfield Hospital, Leicester, UK. · 5 Hypertension Section, Internal Medicine Department, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina. · 6 Paris Descartes University, Paris, France. · 7 Assistance-Publique Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Hypertension Unit, Paris, France. · 8 Institut national de la santé et de la recherche médicale, Centre d'Investigation Clinique 1418, Paris, France. · 9 Normandie Université, UNICAEN, Inserm U1237, CHU Caen Normandie, Caen, France. · 10 Department of Clinical and Experimental Medicine University of Pisa, Pisa, Italy. · 11 Department of Medicine, Maastricht University Medical Center, Maastricht, The Netherlands. · 12 Department of Cardiovascular Medicine, Cleveland Clinic Heart and Vascular Institute, Cleveland, OH, USA. · 13 Department of Internal Medicine, Frankel Cardiovascular Center, University of Michigan, Ann Arbor, MI, USA. · 14 University of South Carolina School of Medicine/Greenville, Greenville, SC, USA. · 15 Association belge de patients atteints de Dysplasie Fibromusculaire/FMD Groep België (FMD-Be), Brussels, Belgium. · 16 Department of Hypertension, Institute of Cardiology, Warsaw, Poland. · 17 APHP, Department of Genetics and Centre for Rare Vascular Diseases, Hôpital Européen Georges Pompidou, Paris, France. · 18 INSERM, U970 - PARCC, University Paris Descartes, Sorbonne Paris Cité, Paris, France. · 19 Zena and Michael A Wiener Cardiovascular Institute and Marie-Josée and Henry R. Kravis Center for Cardiovascular Health; Icahn School of Medicine at Mount Sinai, New York, NY, USA. · 20 Division of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, TN, USA. · 21 Fibromuscular Dysplasia Society of America (FMDSA), North Olmsted, OH, USA. · 22 Centro Fisiologia Clinica e Ipertensione, Policlinico Hospital, University of Milan, Milan, Italy. · 23 Department of Medicine, Cardiovascular Medicine Division, University of Virginia, Charlottesville, VA, USA. · 24 Department of Neurology, University of Virginia, Charlottesville, VA, USA. · 25 Department of Nephrology & Hypertension Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium. · 26 Shanghai Institute of Hypertension and Center for Epidemiological Studies and Clinical Trials, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China. · 27 Vascular Medicine Section and Vascular Center, Harvard Medical School, Massachusetts General Hospital, Boston, MA, USA. · 28 Monash University (Central Clinical School of Medicine), Melbourne, VIC, Australia. · 29 Department of Renal Medicine, Alfred Health, Melbourne, VIC, Australia. ·Vasc Med · Pubmed #30648921.

ABSTRACT: This article is a comprehensive document on the diagnosis and management of fibromuscular dysplasia (FMD), which was commissioned by the working group 'Hypertension and the Kidney' of the European Society of Hypertension (ESH) and the Society for Vascular Medicine (SVM). This document updates previous consensus documents/scientific statements on FMD published in 2014 with full harmonization of the position of European and US experts. In addition to practical consensus-based clinical recommendations, including a consensus protocol for catheter-based angiography and percutaneous angioplasty for renal FMD, the document also includes the first analysis of the European/International FMD Registry and provides updated data from the US Registry for FMD. Finally, it provides insights on ongoing research programs and proposes future research directions for understanding this multifaceted arterial disease.

11 Guideline ACOG Practice Bulletin No. 203: Chronic Hypertension in Pregnancy. 2019

Anonymous4800973. · ·Obstet Gynecol · Pubmed #30575676.

ABSTRACT: Chronic hypertension is present in 0.9-1.5% of pregnant women () and may result in significant maternal, fetal, and neonatal morbidity and mortality. The rate of maternal chronic hypertension increased by 67% from 2000 to 2009, with the largest increase (87%) among African American women. This increase is largely secondary to the obesity epidemic and increasing maternal age (). The trend is expected to continue.The purpose of this document is to clarify the criteria used to define and diagnose chronic hypertension before or during pregnancy, to review the effects of chronic hypertension on pregnancy and vice versa, and to appraise the available evidence for management options. The purpose of these revised best practice recommendations is to provide a rational approach to chronic hypertension in pregnancy based on new research data and relevant pathophysiologic and pharmacologic considerations.

12 Guideline ACOG Practice Bulletin No. 202: Gestational Hypertension and Preeclampsia. 2019

Anonymous4790973. · ·Obstet Gynecol · Pubmed #30575675.

ABSTRACT: Hypertensive disorders of pregnancy constitute one of the leading causes of maternal and perinatal mortality worldwide. It has been estimated that preeclampsia complicates 2-8% of pregnancies globally (). In Latin America and the Caribbean, hypertensive disorders are responsible for almost 26% of maternal deaths, whereas in Africa and Asia they contribute to 9% of deaths. Although maternal mortality is much lower in high-income countries than in developing countries, 16% of maternal deaths can be attributed to hypertensive disorders (). In the United States, the rate of preeclampsia increased by 25% between 1987 and 2004 (). Moreover, in comparison with women giving birth in 1980, those giving birth in 2003 were at 6.7-fold increased risk of severe preeclampsia (). This complication is costly: one study reported that in 2012 in the United States, the estimated cost of preeclampsia within the first 12 months of delivery was $2.18 billion ($1.03 billion for women and $1.15 billion for infants), which was disproportionately borne by premature births (). This Practice Bulletin will provide guidelines for the diagnosis and management of gestational hypertension and preeclampsia.

13 Guideline ACOG Practice Bulletin No. 203 Summary: Chronic Hypertension in Pregnancy. 2019

Anonymous4740973. · ·Obstet Gynecol · Pubmed #30575669.

ABSTRACT: Chronic hypertension is present in 0.9-1.5% of pregnant women (1) and may result in significant maternal, fetal, and neonatal morbidity and mortality. The rate of maternal chronic hypertension increased by 67% from 2000 to 2009, with the largest increase (87%) among African American women. This increase is largely secondary to the obesity epidemic and increasing maternal age (1, 2). The trend is expected to continue.The purpose of this document is to clarify the criteria used to define and diagnose chronic hypertension before or during pregnancy, to review the effects of chronic hypertension on pregnancy and vice versa, and to appraise the available evidence for management options. The purpose of these revised best practice recommendations is to provide a rational approach to chronic hypertension in pregnancy based on new research data and relevant pathophysiologic and pharmacologic considerations.

14 Guideline ACOG Practice Bulletin No. 202 Summary: Gestational Hypertension and Preeclampsia. 2019

Anonymous4730973. · ·Obstet Gynecol · Pubmed #30575668.

ABSTRACT: Hypertensive disorders of pregnancy constitute one of the leading causes of maternal and perinatal mortality worldwide. It has been estimated that preeclampsia complicates 2-8% of pregnancies globally (). In Latin America and the Caribbean, hypertensive disorders are responsible for almost 26% of maternal deaths, whereas in Africa and Asia they contribute to 9% of deaths. Although maternal mortality is much lower in high-income countries than in developing countries, 16% of maternal deaths can be attributed to hypertensive disorders (). In the United States, the rate of preeclampsia increased by 25% between 1987 and 2004 (). Moreover, in comparison with women giving birth in 1980, those giving birth in 2003 were at 6.7-fold increased risk of severe preeclampsia (). This complication is costly: one study reported that in 2012 in the United States, the estimated cost of preeclampsia within the first 12 months of delivery was $2.18 billion ($1.03 billion for women and $1.15 billion for infants), which was disproportionately borne by premature births (). This Practice Bulletin will provide guidelines for the diagnosis and management of gestational hypertension and preeclampsia.

15 Guideline ESC Council on hypertension position document on the management of hypertensive emergencies. 2019

van den Born, Bert-Jan H / Lip, Gregory Y H / Brguljan-Hitij, Jana / Cremer, Antoine / Segura, Julian / Morales, Enrique / Mahfoud, Felix / Amraoui, Fouad / Persu, Alexandre / Kahan, Thomas / Agabiti Rosei, Enrico / de Simone, Giovanni / Gosse, Philippe / Williams, Bryan. ·Department of Internal Medicine, Division of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands. · Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK. · Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Faculty of Health, Aalborg University, Aalborg, Denmark. · Hypertension Division, University Medical Centre Ljubljana, Department of Internal Medicine, Dr. Peter Držaj Hospital, Ljubljana, Slovenia. · Hypertension Unit, Department of Cardiology, Hopital Saint André and University Hospital of Bordeaux, Bordeaux, France. · Hypertension Unit, Department of Nephrology, Hospital 12 de Octubre, Madrid, Spain. · Department for Internal Medicine III, Cardiology, Angiology, and Intensive Care Medicine, Saarland University, Homburg/Saar, Germany. · Division of Cardiology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, and Pole of Cardiovascular Research, Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Brussels, Belgium. · Karolinska Institutet, Department of Clinical Sciences, Danderyd Hospital, Division of Cardiovascular Medicine, Stockholm, Sweden. · Clinica Medica Generale, Department of Clinical and Experimental Sciences, University of Brescia, and Department of Medicine, Azienda Spedali Civili di Brescia, Brescia, Italy. · Hypertension Research Center, Department of Translational Medical Sciences, Federico II University Hospital, Naples, Italy. · University College London (UCL) and UCL Hospitals, London, UK. ·Eur Heart J Cardiovasc Pharmacother · Pubmed #30165588.

ABSTRACT: Hypertensive emergencies are those situations where very high blood pressure (BP) values are associated with acute organ damage, and therefore, require immediate, but careful, BP reduction. The type of acute organ damage is the principal determinant of: (i) the drug of choice, (ii) the target BP, and (iii) the timeframe in which BP should be lowered. Key target organs are the heart, retina, brain, kidneys, and large arteries. Patients who lack acute hypertension-mediated end organ damage do not have a hypertensive emergency and can usually be treated with oral BP-lowering agents and usually discharged after a brief period of observation.

16 Guideline [2018 ESC/ESH Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH)]. 2018

Williams, Bryan / Mancia, Giuseppe / Spiering, Wilko / Rosei, Enrico Agabiti / Azizi, Michel / Burnier, Michel / Clement, Denis L / Coca, Antonio / de Simone, Giovanni / Dominiczak, Anna / Kahan, Thomas / Mahfoud, Felix / Redon, Josep / Ruilope, Luis / Zanchetti, Alberto / Kerins, Mary / Kjeldsen, Sverre E / Kreutz, Reinhold / Laurent, Stephane / Lip, Gregory Y H / McManus, Richard / Narkiewicz, Krzysztof / Ruschitzka, Frank / Schmieder, Roland E / Shlyakhto, Evgeny / Tsioufis, Costas / Aboyans, Victor / Desormais, Ileana. · ·G Ital Cardiol (Rome) · Pubmed #30520455.

ABSTRACT:

17 Guideline [2018 ESC/ESH Guidelines for the Management of Arterial Hypertension: What's New with Regard to Our Older People?] 2018

Hoffmann, Ute / Thrun, Jan-Marc. ·Klinik für Allgemeine Innere Medizin und Geriatrie, Angiologie, Diabetologie, Endokrinologie, Nephrologie, Krankenhaus Barmherzige Brüder Regensburg. ·Dtsch Med Wochenschr · Pubmed #30508852.

ABSTRACT: In the "2018 ESC/ESH Guidelines for the management of arterial hypertension" there are new blood pressure (BP) recommendations with regard to older patients based on randomized controlled trials and well-conducted meta-analyses performed during the last years.It is recommended to base the diagnosis of hypertension on repeated office BP measurements under standardized conditions and in older people in out-of-office BP measurement with ABPM and/or HBPM if logistically and economically feasible. Furthermore lying and standing BP measurements should also be considered in subsequent visits in older people to exclude orthostatic hypotension.Older people should measure their BP in upper arms by validated devices with a well readable display.In the new guidelines more attention is directed on frailty, concomitant treatments and independence influencing the likely tolerability of BP-lowering medications. In fit older patients, it is now recommended that systolic BP should be targeted to a BP range of 130 - 139 mmHg, if tolerated.Lifestyle changes are also recommended in elder patients. Preferred combination therapies are a RAS blocker with a CCB or thiazid diuretic, preferably in a "single pill". When combination therapy is used, this should be initiated at the lowest available doses in elder people.

18 Guideline Recommendations of the Polish Society of Gynecologists and Obstetricians regarding caesarean sections. 2018

Wielgos, Miroslaw / Bomba-Opoń, Dorota / Breborowicz, Grzegorz H / Czajkowski, Krzysztof / Debski, Romuald / Leszczynska-Gorzelak, Bozena / Oszukowski, Przemyslaw / Radowicki, Stanislaw / Zimmer, Mariusz. ·1st Chair and Department of Obstetrics and Gynecology, Medical University of Warsaw, Poland. dbomba@wum.edu.pl. ·Ginekol Pol · Pubmed #30508218.

ABSTRACT: -- No abstract --

19 Guideline 2018 Practice Guidelines for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. 2018

Williams, Bryan / Mancia, Giuseppe / Spiering, Wilko / Agabiti Rosei, Enrico / Azizi, Michel / Burnier, Michel / Clement, Denis / Coca, Antonio / De Simone, Giovanni / Dominiczak, Anna / Kahan, Thomas / Mahfoud, Felix / Redon, Josep / Ruilope, Luis / Zanchetti, Alberto / Kerins, Mary / Kjeldsen, Sverre / Kreutz, Reinhold / Laurent, Stéphane / Lip, Gregory Y H / McManus, Richard / Narkiewicz, Krzysztof / Ruschitzka, Frank / Schmieder, Roland / Shlyakhto, Evgeny / Tsioufis, Konstantinos / Aboyans, Victor / Desormais, Ileana. ·a University College London, London UCL , London , United Kingdom of Great Britain and Northern Ireland. · b IRCCS Instituto Auxologico Italiano , University of Milano-Bicocca , Milano , Italy. · c Department of Medicine , University Medical Center Utrecht , Utrecht , Netherlands. · d Universita degli Studi di Brescia Aree Disciplinari Medicina e Chirurgia , Brescia , Italy. · e Universite Paris Descartes , Paris , France. · f Centre Hospitalier Universitaire Vaudois , Lausanne , Switzerland. · g University of Gent , Gent , Belgium. · h School of Medicine , University of Barcelona , Barcelona , Spain. · i Hypertension Research Center (CIRIAPA), Department of Translational Medical Sciences , Federico II University Hospital , Napoli , Italy. · j University of Glasgow , Glasgow , United Kingdom of Great Britain and Northern Ireland. · k Karolinska Institutet , Stockholm , Sweden. · l Saarland University Hospital , Homburg , Germany. · m Servicio de Medicina Interna del Hospital Clínico de Valencia , Catedrático de Medicina de la Universidad de Valencia , Valencia , Spain. · n Hypertension Unit , Madrid , Spain. · o University of Milan , Milan , Italy. · p Dublin St. James Hospital , Dublin , Ireland. · q Department of Cardiology , Oslo University Hospital , Oslo , Norway. · r Institute for Clinical Medicine , University of Oslo , Oslo , Norway. · s Institut für Klinische Pharmakologie und Toxikologie , Charité - Universitätsmedizin Berlin , Berlin , Germany. · t Hopital Europeen Georges Pompidou , Paris , France. · u College of Medical and Dental Sciences , University of Birmingham , Birmingham , United Kingdom of Great Britain and Northern Ireland. · v Nuffield Department of Primary Care , Nuffield , United Kingdom of Great Britain and Northern Ireland. · w Department of Hypertension and Diabetology , Medical University of Gdansk , Gdansk , Poland. · x Department of Cardiology , University of Zurich , Zurich , Switzerland. · y Abteilung für Nephrologie und Hypertensiologie , Universitätsklinikum Erlangen , Erlangen , Germany. · z Almazov Federal Heart , Blood and Endocrinology Centre , St Petersburg , Russian Federation. · aa Hippokration Hospital, First Cardiology Clinic, Medical School , National and Kapodistrian University of Athens , Athens , Greece. · ab Department of Cardiology , Dupuytren University Hospital , Limoges , France. · ac CHU de Limoges , Limoges , France. ·Blood Press · Pubmed #30380928.

ABSTRACT: These practice guidelines on the management of arterial hypertension are a concise summary of the more extensive ones prepared by the Task Force jointly appointed by the European Society of Hypertension and the European Society of Cardiology. These guidelines have been prepared on the basis of the best available evidence on all issues deserving recommendations; their role must be educational and not prescriptive or coercive for the management of individual subjects who may differ widely in their personal, medical and cultural characteristics. The members of the Task Force have participated independently in the preparation of these guidelines, drawing on their academic and clinical experience and by objective examination and interpretation of all available literature. A disclosure of their potential conflict of interest is reported on the websites of the ESH and the ESC.

20 Guideline Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association. 2018

Carey, Robert M / Calhoun, David A / Bakris, George L / Brook, Robert D / Daugherty, Stacie L / Dennison-Himmelfarb, Cheryl R / Egan, Brent M / Flack, John M / Gidding, Samuel S / Judd, Eric / Lackland, Daniel T / Laffer, Cheryl L / Newton-Cheh, Christopher / Smith, Steven M / Taler, Sandra J / Textor, Stephen C / Turan, Tanya N / White, William B / Anonymous3090966. · ·Hypertension · Pubmed #30354828.

ABSTRACT: Resistant hypertension (RH) is defined as above-goal elevated blood pressure (BP) in a patient despite the concurrent use of 3 antihypertensive drug classes, commonly including a long-acting calcium channel blocker, a blocker of the renin-angiotensin system (angiotensin-converting enzyme inhibitor or angiotensin receptor blocker), and a diuretic. The antihypertensive drugs should be administered at maximum or maximally tolerated daily doses. RH also includes patients whose BP achieves target values on ≥4 antihypertensive medications. The diagnosis of RH requires assurance of antihypertensive medication adherence and exclusion of the "white-coat effect" (office BP above goal but out-of-office BP at or below target). The importance of RH is underscored by the associated risk of adverse outcomes compared with non-RH. This article is an updated American Heart Association scientific statement on the detection, evaluation, and management of RH. Once antihypertensive medication adherence is confirmed and out-of-office BP recordings exclude a white-coat effect, evaluation includes identification of contributing lifestyle issues, detection of drugs interfering with antihypertensive medication effectiveness, screening for secondary hypertension, and assessment of target organ damage. Management of RH includes maximization of lifestyle interventions, use of long-acting thiazide-like diuretics (chlorthalidone or indapamide), addition of a mineralocorticoid receptor antagonist (spironolactone or eplerenone), and, if BP remains elevated, stepwise addition of antihypertensive drugs with complementary mechanisms of action to lower BP. If BP remains uncontrolled, referral to a hypertension specialist is advised.

21 Guideline 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. 2018

Whelton, Paul K / Carey, Robert M / Aronow, Wilbert S / Casey, Donald E / Collins, Karen J / Dennison Himmelfarb, Cheryl / DePalma, Sondra M / Gidding, Samuel / Jamerson, Kenneth A / Jones, Daniel W / MacLaughlin, Eric J / Muntner, Paul / Ovbiagele, Bruce / Smith, Sidney C / Spencer, Crystal C / Stafford, Randall S / Taler, Sandra J / Thomas, Randal J / Williams, Kim A / Williamson, Jeff D / Wright, Jackson T. ·American Society for Preventive Cardiology Representative. †ACC/AHA Representative. ‡Lay Volunteer/Patient Representative. §Preventive Cardiovascular Nurses Association Representative. ‖American Academy of Physician Assistants Representative. ¶Task Force Liaison. #Association of Black Cardiologists Representative. **American Pharmacists Association Representative. ††ACC/AHA Prevention Subcommittee Liaison. ‡‡American College of Preventive Medicine Representative. §§American Society of Hypertension Representative. ‖‖Task Force on Performance Measures Liaison. ¶¶American Geriatrics Society Representative. ##National Medical Association Representative. ·Circulation · Pubmed #30354655.

ABSTRACT: -- No abstract --

22 Guideline 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. 2018

Whelton, Paul K / Carey, Robert M / Aronow, Wilbert S / Casey, Donald E / Collins, Karen J / Dennison Himmelfarb, Cheryl / DePalma, Sondra M / Gidding, Samuel / Jamerson, Kenneth A / Jones, Daniel W / MacLaughlin, Eric J / Muntner, Paul / Ovbiagele, Bruce / Smith, Sidney C / Spencer, Crystal C / Stafford, Randall S / Taler, Sandra J / Thomas, Randal J / Williams, Kim A / Williamson, Jeff D / Wright, Jackson T. ·American Society for Preventive Cardiology Representative. †ACC/AHA Representative. ‡Lay Volunteer/Patient Representative. §Preventive Cardiovascular Nurses Association Representative. ‖American Academy of Physician Assistants Representative. ¶Task Force Liaison. #Association of Black Cardiologists Representative. **American Pharmacists Association Representative. ††ACC/AHA Prevention Subcommittee Liaison. ‡‡American College of Preventive Medicine Representative. §§American Society of Hypertension Representative. ‖‖Task Force on Performance Measures Liaison. ¶¶American Geriatrics Society Representative. ##National Medical Association Representative. ·Circulation · Pubmed #30354654.

ABSTRACT: -- No abstract --

23 Guideline ACVIM consensus statement: Guidelines for the identification, evaluation, and management of systemic hypertension in dogs and cats. 2018

Acierno, Mark J / Brown, Scott / Coleman, Amanda E / Jepson, Rosanne E / Papich, Mark / Stepien, Rebecca L / Syme, Harriet M. ·Department of Medicine, College of Veterinary Medicine, Midwestern University, 5715 W. Utopia Rd, Glendale Arizona 85308. · College of Veterinary Medicine, University of Georgia, Athens, Georgia. · Department of Clinical Science and Services, Royal Veterinary College, London, United Kingdom. · College of Veterinary Medicine, North Carolina State University, Raleigh, North Carolina. · Department of Medical Sciences, University of Wisconsin School of Veterinary Medicine, Madison, Wisconsin. ·J Vet Intern Med · Pubmed #30353952.

ABSTRACT: An update to the 2007 American College of Veterinary Internal Medicine (ACVIM) consensus statement on the identification, evaluation, and management of systemic hypertension in dogs and cats was presented at the 2017 ACVIM Forum in National Harbor, MD. The updated consensus statement is presented here. The consensus statement aims to provide guidance on appropriate diagnosis and treatment of hypertension in dogs and cats.

24 Guideline Canadian Cardiovascular Harmonized National Guidelines Endeavour (C-CHANGE) guideline for the prevention and management of cardiovascular disease in primary care: 2018 update. 2018

Tobe, Sheldon W / Stone, James A / Anderson, Todd / Bacon, Simon / Cheng, Alice Y Y / Daskalopoulou, Stella S / Ezekowitz, Justin A / Gregoire, Jean C / Gubitz, Gord / Jain, Rahul / Keshavjee, Karim / Lindsay, Patty / L'Abbe, Mary / Lau, David C W / Leiter, Lawrence A / O'Meara, Eileen / Pearson, Glen J / Rabi, Doreen M / Sherifali, Diana / Selby, Peter / Tu, Jack V / Wharton, Sean / Walker, Kimberly M / Hua-Stewart, Diane / Liu, Peter P. ·Libin Cardiovascular Institute, Cumming School of Medicine (Anderson), University of Calgary, Calgary, Alta. · Department of Health, Kinesiology, and Applied Physiology (Bacon), Concordia University, Montreal, Que. & Montreal Behavioural Medicine Centre, CIUSSS-NIM, Montreal, Que. · St. Michael's Hospital (Cheng), University of Toronto, Toronto, Ont. · McGill University (Daskalopoulou), Montreal, Que. · Department of Medicine (Ezekowitz), University of Alberta, Edmonton, Alta. · Institut de cardiologie de Montreal (Gregoire), Montreal, Que. · Universite de Montreal (Gubitz), Montreal, Que. · Sunnybrook Research Institute (Hua-Stewart), Toronto, Ont. · Department of Family and Community Medicine (Jain), Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ont. · Institute of Health Policy, Management and Evaluation (Keshavjee), University of Toronto, Toronto, Ont. · Department of Nutritional Sciences (L'Abbe), University of Toronto, Toronto, Ont. · Department of Medicine and Libin Cardiovascular Institute (Lau), Cumming School of Medicine, University of Calgary, Calgary, Alta. · Li Ka Shing Knowledge Institute (Leiter), St. Michael's Hospital, University of Toronto, Toronto, Ont. · Heart and Stroke Foundation (Lindsay), Ottawa, Ont. · Ottawa Heart Institute (Liu), University of Ottawa, Ottawa, Ont. · Insitut de Cardiologie de Montreal (O'Meara), Universite de Montreal, Montreal, Que. · Division of Cardiology, Mazankowski Alberta Heart Institute · University of Alberta, Faculty of Medicine and Dentistry (Pearson), Edmonton, Alta. · Departments of Medicine, Community Health and Cardiac Sciences (Rabi), University of Calgary, Calgary, Alta. · Centre for Addiction and Mental Health, Departments of Family and Community Medicine, Psychiatry and Public Health Sciences (Selby), University of Toronto, Toronto, Ont. · School of Nursing and Health Research Methods, Evidence and Impact, Faculty of Health Sciences (Sherifali), McMaster University, Hamilton, Ont. · Libin Cardiovascular Institute (Stone), University of Calgary, Calgary, Alta. · Division of Nephrology (Tobe), Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ont. · ICES, Sunnybrook Research Institute (Tu), University of Toronto, Toronto, Ont. · St. Joseph's Health Care Centre (Walker), Toronto, Ont. · McMaster University (Wharton), Hamilton Ont. · York University (Wharton), Toronto, Ont. ·CMAJ · Pubmed #30301743.

ABSTRACT: -- No abstract --

25 Guideline Screening and Management of High Blood Pressure in Children and Adolescents. 2018

Khoury, Michael / Madsen, Nicolas. ·Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio. ·JAMA Pediatr · Pubmed #30242318.

ABSTRACT: -- No abstract --

Next